EXTENDED INTERVAL DOSING OF OCRELIZUMAB REDUCES RISK OF DEVELOPING HYPOGAMMAGLOBULINAEMIA

被引：2
|
作者：
Allen, Christopher [1 ]
Russell, Melanie [2 ]
Pendlebury, Jessica [3 ]
Vollmer, Brandi [4 ]
Moswela, Olivia [5 ]
Raza, Pranee-Ta [6 ]
Garjani, Afagh
Abdel-Fahim, Rasha [7 ]
Tallantyre, Emma [8 ]
Evangelou, Nikos [1 ]
机构：
[1] Univ Nottingham, Nottingham, England
[2] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England
[3] Salford Royal NHS Fdn Trust, Salford, Lancs, England
[4] Univ Colorado, Dept Neurol, Boulder, CO USA
[5] Oxford Univ Hosp NHS Fdn Trust, Oxford, England
[6] Cleveland Clin, Cleveland, OH USA
[7] Nottingham Univ Hosp NHS Trust, Nottingham, England
[8] Cardiff Univ, Div Psychol Med & Clin Neurosci, Cardiff, Wales
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2022年 / 93卷 / 09期
关键词：
D O I：
10.1136/jnnp-2022-abn2.26
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Extended interval dosing of natalizumab: is efficacy preserved?
    Clerico, M.
    Signori, A.
    De Mercanti, S.
    Cordioli, C.
    Signoriello, E.
    Lus, G.
    Maniscalco, G. T.
    Curti, E.
    Lorefice, L.
    Cocco, E.
    Nociti, V.
    Mirabella, M.
    Baroncini, D.
    Landi, D.
    Mataluni, G.
    Petruzzo, M.
    Lanzillo, R.
    Gandoglia, I.
    Laroni, A.
    Frangiamore, R.
    Sartori, A.
    Cavalla, P.
    Costantini, G.
    Sormani, M. P.
    Capra, R.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 282 - 283
  • [42] Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing - similar clinical efficacy with decreased immunoglobulin M deficiency rates
    Rempe, Torge
    Elfasi, Aisha
    Rodriguez, Elsa
    Vasquez, Matthew
    Graves, Jennifer
    Kinkel, Revere
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
  • [43] Extended interval dosing of ocrelizumab modifies the repopulation of B-cell subsets without altering clinical efficacy in multiple sclerosis patients
    Rodriguez-Mogeda, Carla
    Van Lierop, Zoe
    Van der Pol, Susanne M. A.
    Coenen, Loet
    Hogenboom, Laura
    Kamermans, Alwin
    Rodriguez, Ernesto
    Van Horssen, Jack
    Van Kempen, Zoe
    Uitdehaag, Bernard
    Teunissen, Charlotte
    Witte, Maarten
    Killestein, Joep
    De Vries, Elga
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 590 - 591
  • [44] Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience
    Guerrieri, Simone
    Bucca, Chiara
    Nozzolillo, Agostino
    Genchi, Angela
    Zanetta, Chiara
    Cetta, Ilaria
    Rugarli, Giulia
    Gattuso, Irene
    Azzimonti, Matteo
    Rocca, Maria Assunta
    Moiola, Lucia
    Filippi, Massimo
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (09) : 2859 - 2864
  • [45] Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
    Ryerson, Lana Zhovtis
    Foley, John
    Chang, Ih
    Kister, Ilya
    Cutter, Gary
    Metzger, Ryan R.
    Goldberg, Judith D.
    Li, Xiaochun
    Riddle, Evan
    Smirnakis, Karen
    Kasliwal, Rachna
    Ren, Zheng
    Hotermans, Christophe
    Ho, Pei-Ran
    Campbell, Nolan
    NEUROLOGY, 2019, 93 (15) : E1452 - E1462
  • [46] Influence of natalizumab extended interval dosing on the PML risk biomarker L-Selectin
    Schwab, N.
    Schneider-Hohendorf, T.
    Meinl, I.
    Windhagen, S.
    Klotz, L.
    Gross, C.
    Meuth, S.
    Deisenhammer, F.
    Wiendl, H.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 297 - 298
  • [47] Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
    Aurora Zanghì
    Carlo Avolio
    Elisabetta Signoriello
    Gianmarco Abbadessa
    Maria Cellerino
    Diana Ferraro
    Christian Messina
    Stefania Barone
    Graziella Callari
    Elena Tsantes
    Patrizia Sola
    Paola Valentino
    Franco Granella
    Francesco Patti
    Giacomo Lus
    Simona Bonavita
    Matilde Inglese
    Emanuele D’Amico
    Neurotherapeutics, 2022, 19 : 1535 - 1545
  • [48] Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
    Zanghi, Aurora
    Avolio, Carlo
    Signoriello, Elisabetta
    Abbadessa, Gianmarco
    Cellerino, Maria
    Ferraro, Diana
    Messina, Christian
    Barone, Stefania
    Callari, Graziella
    Tsantes, Elena
    Sola, Patrizia
    Valentino, Paola
    Granella, Franco
    Patti, Francesco
    Lus, Giacomo
    Bonavita, Simona
    Inglese, Matilde
    D'Amico, Emanuele
    NEUROTHERAPEUTICS, 2022, 19 (05) : 1535 - 1545
  • [49] Natalizumab extended interval dosing reduces serum trough natalizumab concentrations and a4 integrin receptor occupancy
    Foley, J. F.
    Hoyt, T.
    Christensen, A.
    Riddle, E.
    Plavina, T.
    Seawright, L.
    Metzger, R.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 660 - 661
  • [50] Natalizumab Extended Interval Dosing: Real Life Experience
    Jacques, Francois
    Lebel, Marie-Christine
    Timite, Halilou
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1016 - 1017
12345